Turbocharging Phenotypic Screening with AI to Target mRNA Biology
My interview with Yochi Slonim, co-founder of Israeli-based Anima Biotech, about RNA-targeting small molecule therapeutics
While the pharmaceutical world is investigating biologics or mRNA-based therapies, Yochi Slonim, Israeli technology and biotech entrepreneur and public speaker on the subject of startup building and positioning, is sticking to the classics -- small molecules -- but his strategy comes with a twist.
Yochi is not a classically trained pharmaceutical scienti…
Keep reading with a 7-day free trial
Subscribe to Where Tech Meets Bio to keep reading this post and get 7 days of free access to the full post archives.